泽璟制药:盐酸吉卡昔替尼片治疗重度斑秃的新药上市申请获得受理
Core Viewpoint - Zai Jian Pharmaceutical has received acceptance for its new drug application (NDA) for JAK inhibitor, Jika Xitini Hydrochloride Tablets, aimed at treating severe alopecia areata, marking the second indication for this drug [1] Group 1 - The National Medical Products Administration has issued an acceptance notice for the NDA submitted by Zai Jian Pharmaceutical [1] - Jika Xitini Hydrochloride is a novel JAK inhibitor that significantly inhibits all four subtypes of JAK kinases: JAK1, JAK2, JAK3, and TYK2 [1] - This is the second indication for Jika Xitini Hydrochloride Tablets, with no domestic JAK inhibitors currently approved for treating severe alopecia areata in China [1]